迈向高通量率同步辐射微束放射治疗神经肿瘤临床试验:首例自发性犬脑肿瘤治疗
该研究在临床条件下开展「首例犬」试验,对一只17.5 kg法国斗牛犬疑似胶质瘤的自发性脑肿瘤实施三维适形高通量率同步辐射微束阵列照射,处方PTV最小累积谷剂量2.8 Gy,每束峰剂量20至25 Gy、谷剂量约1 Gy。治疗成功实施,3个月随访症状消失,MRI显示肿瘤缩小87.4%且占位效应减轻、左侧侧脑室恢复正常。作者认为这是首例大动物自发性颅内肿瘤的三维适形同步辐射微束放射治疗。
要点
- 首例犬试验对17.5 kg法国斗牛犬疑似胶质瘤行三维适形同步辐射微束放射治疗。
- PTV(CTV+1 mm)最小累积谷剂量2.8 Gy,每束峰剂量20至25 Gy、谷剂量约1 Gy。
- 3个月随访症状消失,MRI示肿瘤缩小87.4%,左侧侧脑室恢复正常。
核心结论
- 作者认为该兽医神经肿瘤试验是首例大动物自发性颅内肿瘤的三维适形同步辐射x射线微束放射治疗。
- 作者认为这是同步辐射微束放射治疗近期临床转化前的重要最后一步,用以证明使用同步辐射微束治疗深部肿瘤的可行性与安全性。
研究设计与样本
- 在临床条件下开展的「首例犬」试验,作为同步辐射微束放射治疗安全临床转化的原理验证与基石。
- 对一只17.5 kg法国斗牛犬(MRI怀疑胶质瘤的自发性脑肿瘤)实施三维适形高通量率同步辐射x射线微束阵列照射。
- 微束宽50 μm、间距400 μm,处方PTV(CTV+1 mm)最小累积谷剂量2.8 Gy,每束峰剂量20至25 Gy、谷剂量约1 Gy。
主要发现
- 治疗成功实施。
- 3个月临床随访显示犬生活质量显著改善,症状消失。
- 照射后3个月MRI显示肿瘤体积缩小87.4%,占位效应减轻,左侧侧脑室恢复正常。
关键数值与推荐
- PTV(CTV+1 mm)最小累积谷剂量2.8 Gy。
- 每束峰剂量20至25 Gy,谷剂量约1 Gy。
- 微束宽50 μm、间距400 μm。
- 照射后3个月肿瘤体积缩小87.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The high potential of microbeam radiation therapy (MRT) in improving tumor control while reducing side effects has been shown by numerous preclinical studies. MRT offers a widened therapeutic window by using the periodical spatial fractionation of synchrotron generated x-rays into an array of intense parallel microbeams. MRT now enters a clinical transfer phase. As proof of principle and cornerstone for the safe clinical transfer of MRT, we conducted a "first in dog" trial under clinical conditions. In this report, we evaluated whether a 3-dimensional conformal MRT can be safely delivered as exclusive radiosurgical treatment in animal patients METHODS AND MATERIALS: We irradiated a 17.5-kg French bulldog for a spontaneous brain tumor (glioma suspected on magnetic resonance imaging) with conformal high-dose-rate microbeam arrays (50-µm-wide microbeams, replicated with a pitch of 400 μm) of synchrotron-generated x-rays. The dose prescription adjusted a minimal cumulated valley dose of 2.8 Gy to the plnning target volume (PTV) (cinical target volume (CTV)+ 1 mm). Thus, each beam delivered 20 to 25 Gy to the target as peak doses, and ∼1 Gy as valley doses RESULTS: The treatment was successfully delivered. Clinical follow-up over 3 months showed a significant improvement of the dog's quality of life: the symptoms disappeared. Magnetic resonance imaging, performed 3 months after irradiation, revealed reduction in tumor size (-87.4%) and mass effect with normalization of the left lateral ventricle. CONCLUSIONS: To our knowledge, this neuro-oncologic veterinary trial is the first 3-dimensional conformal synchrotron x-ray MRT treatment of a spontaneous intracranial tumor in a large animal. It is an essential last step toward the clinical transfer of MRT in the near future to demonstrate the feasibility and safety of treating deep-seated tumors using synchrotron-generated microbeams.
引用
- Adam JF, Balosso J, Bayat S, et al. Toward Neuro-Oncologic Clinical Trials of High-Dose-Rate Synchrotron Microbeam Radiation Therapy: First Treatment of a Spontaneous Canine Brain Tumor. Int J Radiat Oncol Biol Phys. 2022. PMID: 35483539. doi:10.1016/j.ijrobp.2022.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。